24/7
Buzz
Startups
VC
@work
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
DataTech
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Pharmaceuticals
Tags search
HOME
24/7
buzz
STARTUPS
VC
Tech@work
Innovation
OPINIONS
EVENTS
ABOUT
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
15:37
Full list of Israeli high-tech funding rounds in 2023
15:00
Fintech startup Wisor AI raises $8 million in Seed for freight booking software solution
13:17
Japan's ORIX invests in theDOCK’s Navigator II maritime and supply chain fund
12:33
$400 million lawsuit reveals how Eytan Stibbe allegedly scammed his ex-partners in Africa
More stories
Buzz
Most popular
Daily
Weekly
1
Quiet Hiring: The new trend in talent management
2
Fintech startup Wisor AI raises $8 million in Seed for freight booking software solution
3
“Intel faces difficult strategic choices and needs to figure out what the company will look like in the future”
4
Mobileye closing on $35 billion market cap after doubling its valuation in three months
5
EU would view Israel “in the same category as China” if judicial reforms go through
More news
Pharmaceuticals
20 stories about Pharmaceuticals
The Israeli startup using spatial biology to provide better cancer treatment
02.01.22
|
Yafit Ovadia
Nucleai is looking at the way cells interplay and are interspersed within human tissue to develop precision medicine solutions
CytoReason enters Japanese market with SPI partnership
30.09.21
|
James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
Israel’s RedHill Biopharma testing oral pill that cures Covid-19 symptoms
28.02.21
|
Yafit Ovadia
Israeli pharmaceutical company creates treatment to help severe and moderately-ill patients; company generates $90 million in sales annually
Due to high demand for biotech, Pontifax crosses $1.3 billion funding threshold
12.10.20
|
Tzally Greenberg
A series of successful exits and investments see the Israeli fund balloon by 22% to hit $404 million since the start of the Covid-19 crisis
What’s behind the timed resurgence of lawsuits against Teva?
28.08.20
|
Sophie Shulman
The Israeli pharmaceutical giant was hit with three legal blows over the course of a few days
Hitting the Reset Button on Antibiotics
17.04.20
|
Viki Auslender
As the world faces the global threat of Covid-19 and the post antibiotic era, MIT researcher Regina Barzilay and her team are using AI to discover new chemical compounds for medical treatment
Pharmaceutical Company AstraZeneca Launches Digital Health Program in Israel
27.11.19
|
Meir Orbach
Alongside funding, the program will provide Israeli startups with mentorship and training
Teva Quarterly Report Meets Analyst Expectations
07.11.19
|
Sophie Shulman
The Israeli drugmaker’s revenues dropped 6% in the third quarter of 2019 to $4.26 billion. Debt dropped by $1.8 billion to $26.9 billion
Teva Overcomes One Hurdle, Many Still Ahead
23.10.19
|
Hezi Sternlicht
The Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources
Teva to Close Missouri Plant, Report Says
29.08.19
|
Tzally Greenberg
Teva’s manufacturing plant in Israeli city Netanya is also slated for final closure in early 2020, as part of the company’s reorganization plan
Rivals' Earning Reports Should Have Teva's Shareholders Worried
05.08.19
|
Uri Tal-Tene
Teva’s leadership will break its self-imposed silence on Wednesday, when the company publishes its second-quarter report for 2019
Teva to Pay California $69 Million in Narcolepsy Drug Settlement
30.07.19
|
Hezi Sternlicht
The settlement addresses allegations that Teva paid competitors to delay the release of generic versions of Provigil for almost six years, helping Teva maintain a monopoly
Paving the Way to Alzheimer’s Cure, One Algorithm at a Time
19.07.19
|
Tzipi Smilovitz
Israeli scientist Shahar Barbash is making waves in the pharmaceutical world with a new approach to image analysis that has even chemistry Nobel laureate Michael Levitt on board
Pi Therapeutics Raises $19.7 Million
29.05.19
|
Hagar Ravet
Pi Therapeutics develops novel modulators of protein degradation for the treatment of cancer
Derivative Suit Sheds Light on Teva’s Disastrous Rimsa Acquisition
28.05.19
|
Hezi Sternlicht
Teva acquired Mexican drugmaker Rimsa in 2016, but an anonymous email sent a week after the deal’s completion led Teva to launch an internal investigation—and sue the sellers for fraud
Legal Troubles Could Weigh Down Teva’s Ability to Carry its Debt Covenants
16.05.19
|
Uri Tal-Tenne
On one hand, Teva is facing lawsuits that could end up costing it hundreds of millions of dollars; on the other hand, new profitable drugs and a cost-cutting reorganization program. Is it enough to keep its head above water?
Teva’s Shady Legal Past Still Weighs on the Debt-Laden Pharma Company
12.05.19
|
Hezi Sternlicht
On Friday, 43 states joined Connecticut in filing a lawsuit against senior Teva executives and against over a dozen former and current senior executives at leading generic drug companies, alleging all were involved in a drug price-fixing conspiracy
Teva Completes $47.5 Million Sale of Northern Israeli Plant to Private Equity Fund FIMI
02.05.19
|
Hezi Sternlicht
Teva is selling the plant following its 2017 plan to ameliorate its crippling debt by divesting non-core businesses and closing or selling many of its manufacturing plants
Can-Fite BioPharma Receives $1 Million From CKD Pharmaceuticals as Part of Expanded Agreement
16.04.19
|
CTech
Israel-based Can-Fite expanded its distribution agreement with the South Korean company in February, and is entitled to up to $5 million more in milestones
Can-Fite BioPharma to Raise $3.2 Million in Direct Offering
04.04.19
|
CTech
The NYSE and Tel Aviv-listed company develops small molecule drugs used in the treatment of liver and inflammatory diseases and cancer
More Articles